Overview

KPL-301 for Subjects With Giant Cell Arteritis

Status:
Completed

Trial end date:
2020-11-25

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new onset or relapsing/refractory giant cell arteritis (GCA).

Phase:

Phase 2

Details

Lead Sponsor:

Kiniksa Pharmaceuticals, Ltd.

Treatments:

Mavrilimumab
Prednisone